Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) EVP Eliyahu Sharon Kalif sold 106,563 shares of the stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $34.10, for a total value of $3,633,798.30. Following the transaction, the executive vice president owned 65,621 shares in the company, valued at approximately $2,237,676.10. This trade represents a 61.89% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Eliyahu Sharon Kalif also recently made the following trade(s):
- On Thursday, May 14th, Eliyahu Sharon Kalif sold 153,251 shares of Teva Pharmaceutical Industries stock. The shares were sold at an average price of $35.61, for a total value of $5,457,268.11.
Teva Pharmaceutical Industries Stock Down 2.4%
TEVA opened at $32.88 on Wednesday. Teva Pharmaceutical Industries Ltd. has a 1-year low of $14.99 and a 1-year high of $37.35. The company has a current ratio of 1.01, a quick ratio of 0.78 and a debt-to-equity ratio of 1.70. The stock has a market capitalization of $37.80 billion, a price-to-earnings ratio of 24.72, a P/E/G ratio of 3.44 and a beta of 0.84. The business has a 50 day moving average of $33.40 and a 200-day moving average of $32.12.
Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $0.53 earnings per share for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%.The company had revenue of $3.98 billion during the quarter. As a group, sell-side analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.36 earnings per share for the current year.
Analysts Set New Price Targets
TEVA has been the subject of several research reports. Piper Sandler reissued an "overweight" rating and issued a $42.00 price objective (up from $41.00) on shares of Teva Pharmaceutical Industries in a research report on Thursday, April 30th. Weiss Ratings reissued a "sell (d-)" rating on shares of Teva Pharmaceutical Industries in a research report on Monday, April 20th. Barclays increased their price objective on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the company an "overweight" rating in a research report on Wednesday, May 6th. UBS Group increased their price objective on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a "buy" rating in a research report on Thursday, April 30th. Finally, Truist Financial increased their price objective on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a "buy" rating in a research report on Thursday, April 30th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $41.78.
Get Our Latest Research Report on Teva Pharmaceutical Industries
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Global Retirement Partners LLC lifted its position in Teva Pharmaceutical Industries by 27.3% in the fourth quarter. Global Retirement Partners LLC now owns 1,360 shares of the company's stock worth $42,000 after purchasing an additional 292 shares during the period. Captrust Financial Advisors lifted its position in Teva Pharmaceutical Industries by 2.1% in the fourth quarter. Captrust Financial Advisors now owns 14,715 shares of the company's stock worth $459,000 after purchasing an additional 302 shares during the period. Banque Cantonale Vaudoise lifted its position in Teva Pharmaceutical Industries by 6.3% in the fourth quarter. Banque Cantonale Vaudoise now owns 5,133 shares of the company's stock worth $160,000 after purchasing an additional 306 shares during the period. Ethic Inc. lifted its position in Teva Pharmaceutical Industries by 1.8% in the fourth quarter. Ethic Inc. now owns 18,127 shares of the company's stock worth $566,000 after purchasing an additional 325 shares during the period. Finally, Allworth Financial LP lifted its position in Teva Pharmaceutical Industries by 53.8% in the fourth quarter. Allworth Financial LP now owns 941 shares of the company's stock worth $29,000 after purchasing an additional 329 shares during the period. 54.05% of the stock is owned by institutional investors.
About Teva Pharmaceutical Industries
(
Get Free Report)
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.
Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
